iDEL Therapeutics GmbH | $10,381,635 | (Mar 18, 2026)
Surf AI(1) | $57,000,000 | (Mar 18, 2026)
R1 Therapeutics | $77,500,000 | (Mar 18, 2026)
SEQUENTIAL
United States
- New York City
- 18/03/2026
- Unknown
- $3,500,000
Sequential advances personal care and health research by studying the real-world impact of products through human clinical testing, biomarker discovery, and next-generation formulations across skin, scalp, oral, and vaginal care. Our end-to-end, in-house platform, from study design and participant recruitment (tailored to any required criteria) to laboratory analysis and data interpretation, turns complex biological data into clear, actionable insights. By combining microbial and molecular analyses, we enable the development of credible, effective, and trustworthy products and claims. With a database of over 50,000 samples, 4,000+ ingredients, and 10,000+ participants worldwide, Sequential leverages years of scientific expertise to set the standard for data-driven innovation and product validation in the personal care and pharmaceutical industries.
- Industry Biotechnology Research
- Website https://www.sequential.bio/
- LinkedIn https://www.linkedin.com/company/sequentialbio/
Related People
Oliver WorsleyCo Founder
United Kingdom -
Cambridge, England
As Co-Founder and CEO of Sequential, a global leader in skin microbiome research, I drive innovation in genomics to revolutionize skin health. Backed by $7.5 million in funding from Innovate UK, Corundum Systems Biology and other world-class investors, our team has analyzed over 50K+ clinical skin samples to characterise conditions such as acne and atopic dermatitis. My leadership focuses on empowering companies with actionable, data-driven insights for personal care and pharmaceutical applications.
With over seven years of experience leading biotechnology ventures, I bring expertise in molecular biology, epigenetics, and microbiome research. By fostering collaborations across our labs in Cambridge, New York, and Singapore, I aim to bridge cutting-edge genomics research with solutions that improve human health.
Quorus | $5,000,000 | (Mar 18, 2026)
BambooBox | $6,600,000 | (Mar 18, 2026)
Conduit Health | $17,000,000 | (Mar 18, 2026)
Turquoise(US) | $40,000,000 | (Mar 18, 2026)
Malama Health | $9,200,000 | (Mar 17, 2026)
AgZen | $10,000,000 | (Mar 17, 2026)